Cover Image
市場調查報告書

DNA疫苗:技術和全球市場

DNA Vaccines: Technologies and Global Markets

出版商 BCC Research 商品編碼 308693
出版日期 內容資訊 英文 169 Pages
訂單完成後即時交付
價格
Back to Top
DNA疫苗:技術和全球市場 DNA Vaccines: Technologies and Global Markets
出版日期: 2014年07月23日 內容資訊: 英文 169 Pages
簡介

全球DNA疫苗市場2013年達2億4,370萬美元規模。預計2014年達3億5,300萬美元,至2019年達27億美金,2014∼2019年5年的年複合成長率為5.8%。

本報告提供DNA疫苗和相關技術市場概要、全球市場的2013年資料、2014年到2019年的預測、加入此市場的主要企業的全面簡介。

第1章 簡介

第2章 摘要

第3章 概要

  • 簡介
  • 本報告包含的DNA疫苗技術
  • 全球DNA疫苗市場
  • DNA疫苗市場成長推動力
  • DNA疫苗技術的生命週期趨勢
  • DNA疫苗技術的商業性趨勢
  • DNA疫苗產業

第4章 DNA疫苗技術

  • 歷史
  • 人類免疫系
  • 疫苗
  • DNA疫苗

第5章 DNA疫苗的用途

  • 研究工具的應用
  • 臨床的應用
  • DNA疫苗臨床實驗流程概要
  • DNA疫苗臨床實驗摘要
  • 癌症的DNA疫苗臨床實驗
  • 感染疾病
  • 過敏、自體免疫疾病
  • 生化防禦DNA疫苗
  • 動物醫療用DNA疫苗

第6章 DNA疫苗產業

  • 疫苗產業結構的變化
  • 產業結構
  • DNA疫苗產業的競爭
  • DNA疫苗的商業性價值鏈
  • DNA疫苗競爭企業的策略性地位
  • 研究開發的焦點
  • 2014年4月目前科學、技術性委託
  • 產業的收購與策略性聯盟

第7章 疫苗市場

  • 成長推動力
  • 市場預測
    • 概要
    • 各最終用途
    • 研究工具市場
    • 臨床實驗市場
    • 癌症疫苗市場
    • 感染疾病用
    • 動物醫療用 其他

第8章 企業簡介

圖表

目錄
Product Code: BIO067B

REPORT HIGHLIGHTS

The global market for DNA vaccines was valued at $243.7 million in 2013 and is expected to increase to $305.3 million in 2014, and further to $2.7 billion by 2019, a compound annual growth rate (CAGR) of 54.8% over the five-year period from 2014 through 2019.

This report provides:

  • An overview of the global market for DNA vaccines and related technologies
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Details concerning delivery and synthesis technologies, the forces driving market growth, product formats, and market applications for these products
  • Information most useful for biotechnology, DNA plasmid, gene therapy, DNA delivery, pharmaceutical, vaccine, animal health, and biodefense companies
  • Comprehensive profiles of leading companies in the field as well as updates to alliance, merger, and acquisition activity.

STUDY GOALS AND OBJECTIVES

BCC Research's goal for this study is to determine the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. Our particular interest is to analyze and quantify the DNA vaccines market potential by disease type, end-use market and technology. We also identify emerging growth opportunities in DNA vaccine delivery technologies, adjuvants and synthetic genes.

Our key objective is to present a comprehensive analysis of the emerging DNA vaccine industry, with an emphasis on products and technologies that are commercially important in the 2014 to 2019 time period. The role of DNA vaccines within the overall vaccine industry is examined. We highlight high growth and market potential segments of the industry. This analysis provides a quantitative market basis for biotechnology, pharmaceutical, adjuvant and gene delivery companies to make strategic choices about DNA vaccine technologies and markets. The report will be particularly useful to companies supplying DNA vaccine components and systems, including synthetic genes, DNA delivery technologies and adjuvants.

In addition, the study will benefit a wide range of life-science companies that supply enabling technologies for vaccine discovery and development, such as micro fluidics, nanotechnology, and genomics and proteomics tools.

REASONS FOR DOING THE STUDY

The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular biology, DNA synthesis and immunobiology enable rational design approaches. These technologies allow highly targeted vaccines aimed at specific epitopes. The result is new vaccines for a wider range of diseases than was previously feasible, including a new class of therapeutic vaccines. These new technologies allow pharmaceutical firms to discover and develop high-value vaccines for novel applications, creating a substantial new market opportunity.

DNA vaccines have many potential advantages, including specific targeting, use of multiple genes to enhance immunity, and reduced risk compared with conventional vaccines. Translating the advantages of DNA vaccines into the clinic has historically been difficult; however, new advances in the fields of vaccine design and DNA delivery are addressing the previous issues. Achievements in these fields promise to overcome the translational hurdles and create strategic opportunity. This report analyzes these trends and their effects on the future markets for DNA vaccines.

The technological and structural changes occurring in the vaccine industry are strong driving forces for revitalizing this particular market and providing new growth opportunities. It is important that biotechnology and pharmaceutical firms understand the technology and market dynamics within this industry in order to best develop strategic plans and actions.

Based on these market and technology dynamics, it is especially timely to examine the future DNA vaccines markets.

SCOPE OF REPORT

The study scope includes DNA vaccine products that are commercial or likely to be commercialized within the next five years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2014 through 2019 is estimated.

The role that DNA vaccines play in the overall vaccines industry is examined, as well as how the vaccine industry structure and dynamics are changing.

We examine DNA synthesis, biotechnology and pharmaceuticals firms, strategic industry alliances, and the role of gene delivery and synthesis technologies. The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies and biodefense, are analyzed, and the main companies in these fields are highlighted.

TABLE A
SCOPE OF REPORT

Technologies
Covered in This ReportNot Covered in This Report
pDNA vaccines-both therapeutic and preventiveViral vector vaccines
pDNA delivery technologies Traditional vaccines

      Source: BCC Research

ANALYST CREDENTIALS

Jon Evans has been involved in business development and research for the medical industry since 1984. Mr. Evans' career includes four years as a diagnostic systems sales representative and over 15 years in market research and strategy analysis with Fortune 500 clients. He has developed expertise in assessing the unique business development challenges facing firms in the medical industry and designing strategies to optimize market performance. Mr. Evans received a BS in biology from Rutgers University in 1983, and an MBA in business analysis from San Francisco State University in 1989.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF REPORT
  • TABLE A: SCOPE OF REPORT
  • METHODOLOGY
  • INFORMATION SOURCES
  • RELATED BCC RESEARCH REPORTS
  • ANALYST CREDENTIALS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • INTRODUCTION
  • DNA VACCINE TECHNOLOGIES COVERED IN THIS REPORT
    • TABLE 1: SCOPE OF THIS REPORT
  • GLOBAL MARKET FOR DNA VACCINES
    • TABLE 2: GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 3: GLOBAL VALUE OF HUMAN DNA VACCINE MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
  • FORCES DRIVING DNA VACCINE MARKET GROWTH
    • TABLE 4: DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
  • LIFE CYCLE STATUS OF DNA VACCINE TECHNOLOGIES
    • TABLE 5: LIFE CYCLE STAGE OF VACCINE TYPES
  • COMMERCIAL STATUS OF DNA VACCINE TECHNOLOGIES
    • TABLE 6: COMMERCIAL STATUS OF DNA VACCINES
  • DNA VACCINE INDUSTRY
    • TABLE 7: DNA VACCINE INDUSTRY STRUCTURE

CHAPTER 4 - DNA VACCINE TECHNOLOGIES

  • HISTORY
    • TABLE 8: DNA VACCINE HISTORY
  • THE HUMAN IMMUNE SYSTEM
    • TABLE 9: COMPONENTS OF THE IMMUNE SYSTEM
  • VACCINES
    • VACCINE EVOLUTION
      • FIGURE 1 EVOLUTION OF VACCINE TECHNOLOGIES
    • VACCINE TYPES
      • TABLE 10: VACCINE TYPES
      • Technology Life Cycle Stage of Vaccine Types
        • TABLE 11: TECHNOLOGY LIFE CYCLE STAGE OF VACCINE TYPES
  • DNA VACCINES
    • INTRODUCTION
      • FIGURE 2: MECHANISM OF ACTION OF A DNA VACCINE
    • CHANGING VACCINE PARADIGM
      • TABLE 12: CHANGING VACCINE PARADIGM
      • TABLE 13: ADVANTAGES AND DISADVANTAGES OF DNA VACCINES
      • FIGURE 3: SAFETY AND EFFICACY PROFILE OF DNA VERSUS VIRAL-VECTOR VACCINES
    • FUNCTION AND SCOPE OF DNA VACCINES
      • FIGURE 4: DNA VACCINE FUNCTION AND MARKET SCOPE
      • TABLE 14: EMERGING COMPETITIVE LANDSCAPE FOR DNA VACCINES
    • CANCER DNA VACCINES
      • TABLE 15: CANCER VACCINE TYPES
    • DNA VACCINE TECHNOLOGY VALUE CHAIN
      • FIGURE 5: DNA VACCINE TECHNOLOGY VALUE CHAIN
      • TABLE 16: TECHNOLOGY DRIVERS FOR DNA VACCINE VALUE CHAIN
      • Antigen Discovery
      • Plasmid Design
        • TABLE 17: PLASMID DESIGN OBJECTIVES
        • TABLE 18: WAYS TO OPTIMIZE MAMMALIAN GENE EXPRESSION IN PLASMID DNA
      • Plasmid Manufacture
        • FIGURE 6: CONVENTIONAL AND PLASMID DNA VACCINE PRODUCTION PROCESS
        • TABLE 19: DNA PLASMID QUALITY COMPARISON
      • Delivery Technologies
        • TABLE 20: COMPARISON OF DNA DELIVERY TECHNOLOGIES
      • Uncomplexed pDNA
      • Electroporation
        • FIGURE 7: EP PROCESS SCHEMATIC
      • Liposomes
      • Gold Particles
      • Nanoparticles
      • Bacterial Ghosts
      • Bacteriophages
      • Viruses
        • TABLE 21: IN VIVO VIRAL VECTOR TECHNOLOGIES COMPARED
      • Targeting Technologies
        • FIGURE 8: STRATEGIES FOR TARGETING DENDRITIC CELLS
      • Adjuvant Technologies
        • TABLE 22: DNA VACCINE ADJUVANT TECHNOLOGIES
    • DNA VACCINE TECHNOLOGY NEEDS
      • TABLE 23: TECHNOLOGY NEEDS FOR DNA VACCINES

CHAPTER 5 - DNA VACCINE APPLICATIONS

  • RESEARCH TOOL APPLICATIONS
  • CLINICAL APPLICATIONS
  • OVERVIEW TO DNA VACCINE CLINICAL TRIALS PROCESS
    • TABLE 24: DNA VACCINE DEVELOPMENT FLOW SHEET
    • TABLE 25: DNA VACCINE PRECLINICAL DEVELOPMENT STEPS
    • FIGURE 9: FUTURE VACCINE CLINICAL TRIALS OVERVIEW
  • DNA VACCINE CLINICAL TRIALS SUMMARY
    • TABLE 26: DNA VACCINES CLINICAL TRIALS SUMMARY BY STARTING YEAR, AS OF APRIL 2014
    • TABLE 27: DNA VACCINE CLINICAL PHASE I TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 28: DNA VACCINE CLINICAL PHASE I/II TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 29: DNA VACCINE CLINICAL PHASE II TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 30: DNA VACCINE CLINICAL PHASE II/III TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 31: DNA VACCINE CLINICAL PHASE III TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 32: DNA VACCINE CLINICAL PHASE IV TRIALS SUMMARY, AS OF APRIL 2014
  • CANCER DNA VACCINE CLINICAL TRIALS
    • TABLE 33: DNA VACCINE CANCER CLINICAL TRIALS SUMMARY, AS OF APRIL 2014
    • Melanoma
  • INFECTIOUS DISEASE DNA VACCINES
    • TABLE 34: INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF APRIL 2014
    • HSV
    • HPV
    • Influenza
    • HBV
    • Japanese Encephalitis
    • CMV
    • HIV
  • ALLERGY AND AUTOIMMUNE DISEASE
    • TABLE 35: INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF APRIL 2014
  • BIODEFENSE DNA VACCINES
  • ANIMAL HEALTH DNA VACCINES

CHAPTER 6 - DNA VACCINE INDUSTRY

  • VACCINE INDUSTRY STRUCTURAL SHIFTS
    • TABLE 36: VACCINE INDUSTRY STRUCTURAL SHIFTS
  • INDUSTRY STRUCTURE
    • TABLE 37: VACCINE INDUSTRY STRUCTURE: TRADITIONAL VERSUS EMERGING
    • FIGURE 10: MARKETING OF APPROVED VACCINES IN THE UNITED STATES, 2014 (%)
    • TABLE 38: COMPARISON OF VACCINES AND PHARMACEUTICALS BUSINESSES
  • DNA VACCINE INDUSTRY COMPETITORS
    • TABLE 39: DNA VACCINE INDUSTRY COMPETITOR POSITION
  • DNA VACCINE COMMERCIAL VALUE CHAIN
    • FIGURE 11: DNA VACCINE COMMERCIAL VALUE CHAIN
  • DNA VACCINE COMPETITOR STRATEGIC POSITIONING
    • TABLE 40: LARGE PHARMA VACCINE COMPANY STRATEGIC FOCUS
    • TABLE 41: INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
    • TABLE 42: INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC MARKET FOCUS
    • TABLE 43: SPECIALIZED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
  • RESEARCH & DEVELOPMENT FOCUS
    • TABLE 44: ASTELLAS PHARMA INC. OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 45: BAVARIAN NORDIC OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 46: BEIJING CENTER FOR DISEASE CONTROL AND PREVENTION; MUNICIPAL
  • SCIENCE & TECHNOLOGY COMMISSION OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 47: CITY OF HOPE MEDICAL CENTER, NATIONAL CANCER INSTITUTE (NCI) OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 48: DYNAVAX TECHNOLOGIES CORPORATION OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 49: GLAXOSMITHKLINE OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 50: IMPERIAL COLLEGE LONDON OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 51: MERCK SHARP & DOHME OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 52: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 53: NATIONAL TAIWAN UNIVERSITY HOSPITAL OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 54: SANOFI OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 55: SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 56: U.S. ARMY MEDICAL RESEARCH OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 57: UNIVERSITY OF COLORADO OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 58: UNIVERSITY OF OXFORD OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 59: UNIVERSITY OF WISCONSIN OPEN CLINICAL TRIALS, AS OF APRIL 2014
  • INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES
    • TABLE 60: INDUSTRY ACQUISITIONS AND MERGERS, 2006-2014
    • TABLE 61: DNA VACCINE STRATEGIC ALLIANCES

CHAPTER 7 - DNA VACCINE MARKETS

  • GROWTH DRIVING FORCES
    • TABLE 62: DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
  • MARKET FORECASTS
    • OVERVIEW
      • TABLE 63: GLOBAL VALUE OF PHARMACEUTICAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
    • DNA VACCINE MARKETS BY END USE
      • TABLE 64: GLOBAL VALUE OF DNA VACCINES BY END USE, THROUGH 2019 ($ MILLIONS)
    • DNA VACCINE RESEARCH TOOLS MARKETS
      • TABLE 65: GLOBAL VALUE OF DNA VACCINES RESEARCH TOOLS MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • DNA VACCINE CLINICAL MARKETS
      • TABLE 66: GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
      • Strategic Positioning
        • FIGURE 12: DNA VACCINE STRATEGIC MARKET GRID
      • Allergies
        • TABLE 67: DNA VACCINE ALLERGY MARKET OPPORTUNITIES
      • Cancer Therapeutics
        • TABLE 68: CAUSE OF DEATH, WORLDWIDE, 2004 AND 2030 (% OF ALL DEATHS)
      • Infectious Diseases
    • DNA CANCER VACCINES MARKET
      • TABLE 69: GLOBAL VALUE OF CANCER CLINICAL DNA VACCINES BY INDICATION, THROUGH 2019 ($ MILLIONS)
      • TABLE 70: DNA VACCINE CANCER MARKET OPPORTUNITIES
      • Melanoma
      • Solid Tumors (Including Ovarian, Breast and Small-Cell Lung Cancer)
      • Pancreatic Cancer
    • INFECTIOUS DISEASE DNA VACCINE MARKETS
      • TABLE 71: GLOBAL VALUE OF INFECTIOUS DISEASE CLINICAL DNA VACCINES MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
      • CMV
      • HBV
      • HPV
      • HCV
      • HIV
    • ANIMAL HEALTH DNA VACCINE MARKETS
      • TABLE 72: GLOBAL VALUE OF ANIMAL HEALTH CLINICAL DNA VACCINES MARKET, BY INDICATION, THROUGH 2019 ($ MILLIONS)
      • Canine Melanoma
      • Equine West Nile Virus
      • Leishmaniasis
      • Feline Leukemia Virus
      • Fish Vaccine Adjuvants
    • BIODEFENSE DNA VACCINE MARKETS
      • TABLE 73: GLOBAL VALUE OF BIODEFENSE CLINICAL DNA VACCINES MARKET, BY END USE, THROUGH 2019 ($ MILLIONS)
    • DNA VACCINE MARKETS BY DELIVERY TECHNOLOGY
      • TABLE 74: GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY DELIVERY TECHNOLOGY, THROUGH 2019 ($ MILLIONS)
    • DNA VACCINE MARKET BY FORMAT AND FUNCTION
      • TABLE 75: GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY VACCINE FORMAT, THROUGH 2019 ($ MILLIONS)
      • TABLE 76: GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY FUNCTION, THROUGH 2019 ($ MILLIONS)
    • DNA VACCINES MARKET BY GEOGRAPHICAL REGION
      • TABLE 77: GLOBAL VALUE OF DNA VACCINES MARKET, BY GEOGRAPHICAL REGION, THROUGH 2019 ($ MILLIONS)

CHAPTER 8 - COMPANY PROFILES

  • ADIMMUNE
  • ADVANCED BIOSCIENCE LABORATORIES INC.
  • ALDEVRON LLC
  • ALTEA THERAPEUTICS
  • ALTHEA TECHNOLOGIES INC.
  • ANGES MG INC.
  • AVAX TECHNOLOGIES
  • BAVARIAN NORDIC A/S
  • BIGDNA, LTD.
  • BIOJECT MEDICAL TECHNOLOGIES INC.
  • BTX HARVARD APPARATUS
  • CHANGCHUN BAIKE PHARMACEUTICAL CO. LTD.
  • CHRONTECH PHARMA
  • COBRA BIOMANUFACTURING PLC
  • CRUCELL
  • CYTRX CORP.
  • DENDREON CORP.
  • DYNAVAX TECHNOLOGIES
  • EUROVACC FOUNDATION, THE
  • FIT BIOTECH OYJ PLC
  • GENEART AG
  • GENETIC IMMUNITY
  • GENEXINE
  • GENOMIDEA INC.
  • GENOVAC GMBH
  • GENVEC INC.
  • GEOVAX LABS
  • GLAXOSMITHKLINE
  • GREENPAK BIOTECH LTD.
  • HENDERSON MORLEY PLC
  • ICHOR MEDICAL SYSTEMS INC.
  • IGXBIO INC.
  • IMMUNOMIC THERAPEUTICS INC.
  • IMMUNOVACCINE INC.
  • IN CELL ART
  • INDIAN IMMUNOLOGICALS
  • INOVIO
  • INVIVOGEN
  • JUVARIS BIOTHERAPEUTICS INC.
  • LENTIGEN CORP.
  • MANNKIND CORP.
  • MERCK
    • TABLE 78: MERCK VACCINE PRODUCTS
  • MERIAL LTD.
  • MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
  • MOLOGEN AG
  • MULTIMERIC BIOTHERAPEUTICS INC.
  • NATURE TECHNOLOGY CORP.
  • NIH VACCINE RESEARCH CENTER
  • NOVARTIS
  • OXFORD BIOMEDICA PLC
  • PFIZER
  • PLASMIDFACTORY GMBH & CO.
  • PROFECTUS BIOSCIENCES INC.
  • QED BIOSCIENCE INC.
  • SANOFI-AVENTIS
  • STATENS SERUM INSTITUT
  • SUPRATEK PHARMA
  • TOLERION INC.
  • VALNEVA SE
  • VAXGEN INC.
  • VAXIION THERAPEUTICS INC.
  • VAXONCO INC.
  • VGX PHARMACEUTICALS LLC
  • VGXI INC.
  • VICAL INC.
  • VIROMED CO. LTD.
  • XENETIC BIOSCIENCE INC.
    • TABLE 79: COMPANIES WITH ACTIVE DNA VACCINE CLINICAL TRIALS

LIST OF TABLES

  • TABLE A: SCOPE OF REPORT
  • SUMMARY TABLE: GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: SCOPE OF THIS REPORT
    • TABLE 2: GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 3: GLOBAL VALUE OF HUMAN DNA VACCINE MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 4: DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
    • TABLE 5: LIFE CYCLE STAGE OF VACCINE TYPES
    • TABLE 6: COMMERCIAL STATUS OF DNA VACCINES
    • TABLE 7: DNA VACCINE INDUSTRY STRUCTURE
    • TABLE 8: DNA VACCINE HISTORY
    • TABLE 9: COMPONENTS OF THE IMMUNE SYSTEM
    • TABLE 10: VACCINE TYPES
    • TABLE 11: TECHNOLOGY LIFE CYCLE STAGE OF VACCINE TYPES
    • TABLE 12: CHANGING VACCINE PARADIGM
    • TABLE 13: ADVANTAGES AND DISADVANTAGES OF DNA VACCINES
    • TABLE 14: EMERGING COMPETITIVE LANDSCAPE FOR DNA VACCINES
    • TABLE 15: CANCER VACCINE TYPES
    • TABLE 16: TECHNOLOGY DRIVERS FOR DNA VACCINE VALUE CHAIN
    • TABLE 17: PLASMID DESIGN OBJECTIVES
    • TABLE 18: WAYS TO OPTIMIZE MAMMALIAN GENE EXPRESSION IN PLASMID DNA
    • TABLE 19: DNA PLASMID QUALITY COMPARISON
    • TABLE 20: COMPARISON OF DNA DELIVERY TECHNOLOGIES
    • TABLE 21: IN VIVO VIRAL VECTOR TECHNOLOGIES COMPARED
    • TABLE 22: DNA VACCINE ADJUVANT TECHNOLOGIES
    • TABLE 23: TECHNOLOGY NEEDS FOR DNA VACCINES
    • TABLE 24: DNA VACCINE DEVELOPMENT FLOW SHEET
    • TABLE 25: DNA VACCINE PRECLINICAL DEVELOPMENT STEPS
    • TABLE 26: DNA VACCINES CLINICAL TRIALS SUMMARY BY STARTING YEAR, AS OF APRIL 2014
    • TABLE 27: DNA VACCINE CLINICAL PHASE I TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 28: DNA VACCINE CLINICAL PHASE I/II TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 29: DNA VACCINE CLINICAL PHASE II TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 30: DNA VACCINE CLINICAL PHASE II/III TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 31: DNA VACCINE CLINICAL PHASE III TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 32: DNA VACCINE CLINICAL PHASE IV TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 33: DNA VACCINE CANCER CLINICAL TRIALS SUMMARY, AS OF APRIL 2014
    • TABLE 34: INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 35: INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 36: VACCINE INDUSTRY STRUCTURAL SHIFTS
    • TABLE 37: VACCINE INDUSTRY STRUCTURE: TRADITIONAL VERSUS EMERGING
    • TABLE 38: COMPARISON OF VACCINES AND PHARMACEUTICALS BUSINESSES
    • TABLE 39: DNA VACCINE INDUSTRY COMPETITOR POSITION
    • TABLE 40: LARGE PHARMA VACCINE COMPANY STRATEGIC FOCUS
    • TABLE 41: INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
    • TABLE 42: INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC MARKET FOCUS
    • TABLE 43: SPECIALIZED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
    • TABLE 44: ASTELLAS PHARMA INC. OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 45: BAVARIAN NORDIC OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 46: BEIJING CENTER FOR DISEASE CONTROL AND PREVENTION; MUNICIPAL SCIENCE & TECHNOLOGY COMMISSION OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 47: CITY OF HOPE MEDICAL CENTER, NATIONAL CANCER INSTITUTE (NCI) OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 48: DYNAVAX TECHNOLOGIES CORPORATION OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 49: GLAXOSMITHKLINE OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 50: IMPERIAL COLLEGE LONDON OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 51: MERCK SHARP & DOHME OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 52: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 53: NATIONAL TAIWAN UNIVERSITY HOSPITAL OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 54: SANOFI OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 55: SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 56: U.S. ARMY MEDICAL RESEARCH OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 57: UNIVERSITY OF COLORADO OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 58: UNIVERSITY OF OXFORD OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 59: UNIVERSITY OF WISCONSIN OPEN CLINICAL TRIALS, AS OF APRIL 2014
    • TABLE 60: INDUSTRY ACQUISITIONS AND MERGERS, 2006-2014
    • TABLE 61: DNA VACCINE STRATEGIC ALLIANCES
    • TABLE 62: DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
    • TABLE 63: GLOBAL VALUE OF PHARMACEUTICAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 64: GLOBAL VALUE OF DNA VACCINES BY END USE, THROUGH 2019 ($ MILLIONS)
    • TABLE 65: GLOBAL VALUE OF DNA VACCINES RESEARCH TOOLS MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 66: GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 67: DNA VACCINE ALLERGY MARKET OPPORTUNITIES
    • TABLE 68: CAUSE OF DEATH, WORLDWIDE, 2004 AND 2030 (% OF ALL DEATHS)
    • TABLE 69: GLOBAL VALUE OF CANCER CLINICAL DNA VACCINES BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 70: DNA VACCINE CANCER MARKET OPPORTUNITIES
    • TABLE 71: GLOBAL VALUE OF INFECTIOUS DISEASE CLINICAL DNA VACCINES MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 72: GLOBAL VALUE OF ANIMAL HEALTH CLINICAL DNA VACCINES MARKET, BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 73: GLOBAL VALUE OF BIODEFENSE CLINICAL DNA VACCINES MARKET, BY END USE, THROUGH 2019 ($ MILLIONS)
    • TABLE 74: GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY DELIVERY TECHNOLOGY, THROUGH 2019 ($ MILLIONS)
    • TABLE 75: GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY VACCINE FORMAT, THROUGH 2019 ($ MILLIONS)
    • TABLE 76: GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY FUNCTION, THROUGH 2019 ($ MILLIONS)
    • TABLE 77: GLOBAL VALUE OF DNA VACCINES MARKET, BY GEOGRAPHICAL REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 78: MERCK VACCINE PRODUCTS
    • TABLE 79: COMPANIES WITH ACTIVE DNA VACCINE CLINICAL TRIALS

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
    • FIGURE 1: EVOLUTION OF VACCINE TECHNOLOGIES
    • FIGURE 2: MECHANISM OF ACTION OF A DNA VACCINE
    • FIGURE 3: SAFETY AND EFFICACY PROFILE OF DNA VERSUS VIRAL-VECTOR VACCINES
    • FIGURE 4: DNA VACCINE FUNCTION AND MARKET SCOPE
    • FIGURE 5: DNA VACCINE TECHNOLOGY VALUE CHAIN
    • FIGURE 6: CONVENTIONAL AND PLASMID DNA VACCINE PRODUCTION PROCESS
    • FIGURE 7: EP PROCESS SCHEMATIC
    • FIGURE 8: STRATEGIES FOR TARGETING DENDRITIC CELLS
    • FIGURE 9: FUTURE VACCINE CLINICAL TRIALS OVERVIEW
    • FIGURE 10: MARKETING OF APPROVED VACCINES IN THE UNITED STATES, 2014 (%)
    • FIGURE 11: DNA VACCINE COMMERCIAL VALUE CHAIN
    • FIGURE 12: DNA VACCINE STRATEGIC MARKET GRID
Back to Top